

RESEARCH ARTICLE

Open Access



Transcriptome analysis of complex I-deficient patients reveals distinct expression programs for subunits and assembly factors of the oxidative phosphorylation system

Robin van der Lee^{1†}, Radek Szklarczyk^{1,2†}, Jan Smeitink³, Hubert J M Smeets⁴, Martijn A. Huynen¹ and Rutger Vogel^{3*}

Abstract

Background: Transcriptional control of mitochondrial metabolism is essential for cellular function. A better understanding of this process will aid the elucidation of mitochondrial disorders, in particular of the many genetically unsolved cases of oxidative phosphorylation (OXPHOS) deficiency. Yet, to date only few studies have investigated nuclear gene regulation in the context of OXPHOS deficiency. In this study we performed RNA sequencing of two control and two complex I-deficient patient cell lines cultured in the presence of compounds that perturb mitochondrial metabolism: chloramphenicol, AICAR, or resveratrol. We combined this with a comprehensive analysis of mitochondrial and nuclear gene expression patterns, co-expression calculations and transcription factor binding sites.

Results: Our analyses show that subsets of mitochondrial OXPHOS genes respond opposingly to chloramphenicol and AICAR, whereas the response of nuclear OXPHOS genes is less consistent between cell lines and treatments. Across all samples nuclear OXPHOS genes have a significantly higher co-expression with each other than with other genes, including those encoding mitochondrial proteins. We found no evidence for complex-specific mRNA expression regulation: subunits of different OXPHOS complexes are similarly (co-)expressed and regulated by a common set of transcription factors. However, we did observe significant differences between the expression of nuclear genes for OXPHOS subunits versus assembly factors, suggesting divergent transcription programs. Furthermore, complex I co-expression calculations identified 684 genes with a likely role in OXPHOS biogenesis and function. Analysis of evolutionarily conserved transcription factor binding sites in the promoters of these genes revealed almost all known OXPHOS regulators (including GABP, NRF1/2, SP1, YY1, E-box factors) and a set of novel candidates (ELK1, KLF7, SP4, EHF, ZNF143, and TEL2).

Conclusions: OXPHOS genes share an expression program distinct from other genes encoding mitochondrial proteins, indicative of targeted nuclear regulation of a mitochondrial sub-process. Within the subset of OXPHOS genes we established a difference in expression between mitochondrial and nuclear genes, and between nuclear genes encoding subunits and assembly factors. Most transcription regulators of genes that co-express with complex I are well-established factors for OXPHOS biogenesis. For the remaining six factors we here suggest for the first time a link with transcription regulation in OXPHOS deficiency.

Keywords: Mitochondria, Mitochondrial disorders, Oxidative phosphorylation, Complex I, Assembly factors, Biogenesis, Gene expression, Co-expression, Transcription regulation, Transcription factors

* Correspondence: rutger.vogel@radboudumc.nl

†Equal contributors

³Nijmegen Center for Mitochondrial Disorders, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, PO BOX 9101, 6500 HB Nijmegen, The Netherlands

Full list of author information is available at the end of the article

Background

Mitochondria are the primary source of cellular ATP, which is generated via electron transfer in the oxidative phosphorylation (OXPHOS) system using substrates derived from oxidation of carbohydrates, fatty acids and amino acids. The value of healthy mitochondria becomes evident in cases of OXPHOS deficiency. These metabolic disorders primarily affect tissues with a high ATP demand such as the brain, heart, and skeletal muscle, typically resulting in progressive energy deficiencies and childhood death [1]. Respiratory chain disorders occur in approximately 1:5,000–10,000 living births [2]. The most frequently encountered one is complex I deficiency (OMIM: 252010). No cure for OXPHOS deficiencies exists, and current interventions are either cumbersome or only effective for specific types of the disease [3]. Furthermore, 40–70 % of cases remain genetically unexplained [4, 5] as no mutations are found in the genes encoding structural subunits or assembly factors, impeding genetic counseling. Therefore there is a great need for a better understanding of how the biogenesis and activity of the OXPHOS system is controlled.

Cells can control metabolic output by regulating gene expression. The OXPHOS system is constructed from a combination of nuclear and mitochondrial gene products, e.g. seven genes of complex I are encoded by the mitochondrial DNA and 37 by the nuclear DNA. This bigenomic assembly implies that there are at least two mechanisms for regulating OXPHOS gene expression: mitochondrial and nuclear. Replication, maintenance, and transcription of mitochondrial DNA are tightly regulated processes. Disturbances in any of these processes have been firmly linked to combined OXPHOS deficiency (for a recent review see [6]). In contrast, although much has been published about the relevance of metabolic (co)-regulators such as PGC-1 α , NRF1, NRF2, YY1, and SP1 for the regulation of OXPHOS gene expression, little is known about the possible relationship between disturbed nuclear gene regulation and OXPHOS deficiency.

In this study, we investigate mitochondrial and nuclear gene expression patterns in patients with complex I deficiency under various conditions of perturbed mitochondrial metabolism. Gene expression clustering, co-expression calculations and analysis of transcription factor binding sites provide insights into nuclear transcription regulation of OXPHOS, suggesting regulation of the system as a whole rather than regulation of specific complexes. Our data also reveal that assembly factors follow an expression pattern that is more like genes encoding other mitochondrial proteins than like OXPHOS subunits. Finally, analysis of enriched regulators of nuclear genes co-expressing with complex I not only retrieves virtually all transcription factors (TFs) with a well-known role in the regulation of OXPHOS gene expression, but also identifies several

factors not previously implicated in the regulation of OXPHOS in general or in respiratory chain disease.

Results


Culturing, incubation and RNA sequencing of complex I-deficient patient cells

To investigate patterns of transcription in OXPHOS deficiency, we measured gene expression in two healthy fibroblast cell lines and two fibroblast patient cell lines carrying mutations in complex I genes *NDUFS2* and *ND5* (Fig. 1). Cells were treated with vehicle (DMSO) and three compounds that stimulate or inhibit mitochondrial metabolism in order to trigger a transcriptional response of mitochondrial genes. Chloramphenicol inhibits mitochondrial gene translation and OXPHOS assembly and function [7]. Resveratrol stimulates mitochondrial growth/metabolism via SIRT1/AMPK [8]. AICAR stimulates mitochondrial metabolism as an AMPK agonist [9]. The compound incubations were done in duplicate, resulting in a total of 4 cell lines \times 4 compounds \times 2 replicates = 32 samples. Processing of the RNA sequencing data revealed expression values of 13,684 nuclear DNA encoded genes (referred to as nuclear genes) and 16 mitochondrial DNA encoded genes (referred to as mitochondrial genes) in all samples. We subsequently analyzed the transcriptomes using three approaches: gene expression clustering, co-expression calculations, and transcription factor binding site analysis (Fig. 1).

Of our list of currently known 127 unique OXPHOS subunits and assembly factors (Additional file 1: Table S1), all 13 mitochondrial and 112 nuclear OXPHOS genes were detected in the expression analysis. To investigate the distribution of OXPHOS genes in the 13,700 expression profiles we performed hierarchical clustering (Pearson uncentered, average linkage). Many OXPHOS genes share a distinct expression profile across the experiments and are significantly enriched among a sub-cluster of 1,518 genes (48/1,518 were OXPHOS, Fisher's exact $P < 0.05$, Additional file 2: Figure S1 and Additional file 3: Table S2). Next we analyzed mitochondrial and nuclear OXPHOS gene expression separately.

Differences in expression of mitochondrial OXPHOS genes between cell lines and treatments

mRNA measurements for mtDNA-encoded genes are strongly correlated between biological replicates ($R^2 = 0.88$, see Methods). Total mitochondrial mRNA expression was not significantly different between the four cell lines (one-way ANOVA $P = 0.6$) indicating that differences in the genetic background of our cells do not have a systematic influence on total mitochondrial gene expression. mRNA expression of mitochondrial genes in control vs. patient cells differed less than 1 % implying that the complex I defects do not influence



global mtDNA expression levels (Additional file 2: Figure S2A). We did, however, observe a significant transcriptional response in cells upon perturbation of metabolism using different compounds (4 treatments, one-way ANOVA $P = 0.0002$). The total mitochondrial mRNA expression was 15 % higher upon chloramphenicol treatment compared to control DMSO, and significantly higher than any of the other treatments ($P < 0.0003$ in pairwise comparison with the other groups, two-tailed paired T -test) (Additional file 2: Figure S3). We observed high transcript abundance upon chloramphenicol treatments in all cell types. The variance in chloramphenicol-induced gene expression is very low compared to other treatments and the control condition, suggesting saturation of mitochondrial transcript abundance (Additional file 2: Figure S3). Total mtDNA gene expression levels in AICAR and resveratrol treatments are lower than control 4 % ($P = 0.1$) and 5 % ($P = 0.001$), respectively.

mRNA levels of mitochondrial OXPHOS genes change in response to treatments (Fig. 2a). These changes in transcript levels can be the result of a combination of factors, such as changes in mitochondrial transcription, in mitochondrial mRNA degradation rates, and in trafficking. The direction of mRNA changes upon treatments vary considerably between genes even within the same complex. For example, the transcript level of MT-ND2 increases by 50 % upon chloramphenicol treatment compared to vehicle, while other subunits of complex I (MT-ND4, MT-ND5, MT-ND6) decrease up to 30 % (Fig. 2a and Additional file 2: Figure S4). We did not observe correlations between changes in mitochondrial gene expression and respiratory chain complex, position on the mitochondrial genome or mitochondrial strand of origin (data not shown). However, certain trends are apparent and reproducible. Up-regulation of genes encoding

complex I subunits: MT-ND4, 4L, 5 and 6 upon AICAR treatment (~40 %) and their down regulation in chloramphenicol (~10 %) is significant compared to cells treated with control DMSO ($P < 0.05$ or less for these genes, two-tailed paired T -test). MT-ND2 and, to a lesser extent MT-ND3 and MT-ATP8 show the opposite expression pattern: they are up regulated in chloramphenicol compared to AICAR (140–270 %, $P < 0.05$). Thus, mitochondrial gene expression is similar between cell lines but different upon treatment versus control vehicle, as subsets of mitochondrial OXPHOS genes respond differently to chloramphenicol and AICAR.

Differences in expression of nuclear OXPHOS genes between cell lines and treatments

Examination of the expression data for nuclear genes suggests differences in steady state and treatment-induced OXPHOS mRNA levels between control and patient cell lines, with control 2 generally showing higher nuclear OXPHOS gene expression than the other cell lines (Additional file 2: Figure S2B). Furthermore, the chloramphenicol-induced accumulation of transcripts for a subset of mitochondrial OXPHOS genes (Fig. 2a) is not matched by nuclear OXPHOS mRNA levels (Fig. 2b). For nuclear complex I genes, unsupervised clustering captures similarity of transcriptional responses to AICAR and resveratrol in closely-knit clusters (Additional file 2: Figure S6), but these responses are not consistent for all genes. Nevertheless, combining the gene expression profiles across all cell lines and treatment conditions is highly informative, as will be illustrated in the following sections.

Clustering identifies distinct expression patterns of OXPHOS subunits and assembly factors

Detailed analysis of the expression levels of nuclear OXPHOS genes revealed no specific clusters for individual




Fig. 2 (See legend on next page.)

(See figure on previous page.)

Fig. 2 Mitochondrial OXPHOS genes respond differentially to treatments and assembly factors tend to express differently from nuclear genes encoding OXPHOS subunits. Expression profiles of OXPHOS genes are shown in heatmap representation in 32 RNA sequencing measurements of control and complex I-deficient patient cells. Panel **a** shows the mitochondrial-encoded OXPHOS genes. Panel **b** shows the nuclear-encoded OXPHOS genes. At the top of the figure, controls, patients, and compound incubations are indicated across the samples, where numbers 1 and 2 refer to the cell line. On the right assembly factors and subunits per complex are labeled by color. On the left the central cluster of OXPHOS subunit genes is indicated by a vertical bar. Genes were clustered using average linkage clustering with uncentered Pearson correlation as distance matrix. On the bottom the horizontal bar depicts expression values. A value of 1.0 (black) denotes median log-expression of the gene (see Methods), with green denoting higher and red denoting lower expression levels

OXPHOS complexes, arguing against complex-specific regulation of expression for the evaluated cell types and conditions (Fig. 2b). However, clustering did highlight a distinction between the expression profiles of OXPHOS subunits and assembly factor genes: 67 of the 81 genes (83 %) in the central largest cluster are subunit genes, while 28 of the 32 genes (82 %) in the remaining smaller clusters are assembly genes (Fig. 2b). Thus, although OXPHOS genes share similar expression profiles, subunits cluster together in a distinct group from OXPHOS assembly genes, indicative of differential transcription regulation.

Co-expression confirms absence of OXPHOS complex-specific expression profiles and differential behavior of assembly factors

To identify additional candidates with expression profiles compatible with OXPHOS genes, we calculated co-expression with complex I for all measured nuclear genes by integrating the gene expression profiles (Fig. 1). As expected, known OXPHOS genes as a group have significantly higher co-expression with complex I than do other genes in the genome (Figs. 3a and b, $P = 3.1 \times 10^{-28}$, one-tailed Mann–Whitney U test). However, OXPHOS genes are also more co-expressed with complex I than other genes encoding proteins localized to the mitochondria [10] ($P = 2.5 \times 10^{-15}$). Sub-classification of OXPHOS genes into assembly factors and the structural subunits of the five complexes (Additional file 1: Table S1) revealed no complex-specific co-expression patterns, in agreement with the trends observed in the clustering approach above: complex I co-expression distributions are similar for individual OXPHOS complexes (Fig. 3b, $P = 0.33$, Kruskal–Wallis test). In fact, expression profiles of complexes III, IV and V tend to be more similar to the average profile of complex I (i.e. have higher median complex I co-expression scores) than those of complex I genes themselves, supporting the notion that mRNA expression of OXPHOS genes is jointly regulated. The possible exception is complex II, subunits of which tend to show less co-expression with complex I genes (though not statistically significantly different) than do subunits of complexes III, IV and V.

Interestingly, assembly factors (including those involved in assembly of complex I itself) have a significantly lower

co-expression with complex I than structural subunits ($P = 1.8 \times 10^{-8}$, Kruskal–Wallis test, Fig. 3b) and are more similar to other mitochondrial genes, confirming that their expression profiles are significantly different from OXPHOS subunits (Fig. 2b). Thus, the complex I-like expression profile seems specific for OXPHOS subunits compared to assembly factors or other genes encoding mitochondrial proteins, but does not distinguish individual complexes.

Genes that consistently co-express with complex I under different conditions in different cells are likely to be functionally related, for example by being involved in OXPHOS biogenesis or its regulation. To identify such potential genes we considered the top 5 % of complex I co-expression values, corresponding to a co-expression score cutoff of 0.54 (close to a local peak in the frequency distribution of co-expression scores, Figs. 3 and Additional file 2: Figure S5, Additional file 4: Table S3). This cutoff captures a total of 684 nuclear genes, including 43 % (16/37) of the complex I subunits, 42 % (15/38) of the other OXPHOS subunits, three assembly factors (NDUFAF3, ACAD9, C19orf79) and 96 other known mitochondrial genes. Functional classification of these top-ranking genes using DAVID [11] reveals a program that fits the biogenesis and breakdown of OXPHOS proteins (Additional file 5: Table S4). Gene groups with the highest enrichment scores (ES) other than OXPHOS (37 genes, ES 12, mostly complex I/III/IV/V genes) are translation (51 genes, ES 23, mostly (mito)ribosomal genes), ribonuclear processing (12 genes, ES 8) and quality control (14/15 genes, ES 8/6, mostly ubiquitin and proteasome-related genes). That plasticity in transcription of metabolic/mitochondrial genes is tightly coupled to proteolytic breakdown of the involved activators was recently highlighted by Catic et al. [12] and could explain the enrichment of the latter group. Two additional enriched gene groups are of potential interest. The first group (ES 21) contains PRELID1 (mitochondrial morphology and function) [13], CHCHD2 (regulator of cytochrome oxidase) [14], ISOC2 (tumor development) [15], and MRPL53 (a mitochondrial ribosomal protein also found in [16] in a putative ribonucleotide complex with LRPPRC and SLIRP). The second (ES 7) contains 7 genes including the complex I assembly factor ACAD9, ETFA and ETFB (involved in




Fig. 3 All OXPPOS complexes co-express with complex I, but assembly factors follow divergent transcriptional programs. Histograms (a) and boxplots (b) of co-expression scores with known complex I genes. Genes are grouped as OXPPOS, mitochondrial (nuclear genes encoding proteins with a function in the mitochondria), or other genes in the genome (a). OXPPOS genes are further sub-classified into individual complexes and assembly factors (b). The shaded grey area represents the top 5 % of nuclear genes co-expressing with complex I, which are included in the TF binding site enrichment analysis. The dashed line marks the cutoff score (0.54). Groups are mutually exclusive, i.e. genes occur only in one group; complex I-V genes together with assembly factors make up the OXPPOS group. Histogram counts (a) were normalized to a maximum of 1 for each gene set. Colored boxes in boxplots (b) represent the 50 % of data points above ($\times 0.75$) and below ($\times 0.25$) the median ($\times 0.50$); the black line within the box). Vertical lines (whiskers) connected to the boxes by the horizontal dashed lines represent the largest and the smallest non-outlier data points (which are plotted as individual dots). P values comparing two groups are from Mann-Whitney U tests and those comparing multiple groups are from Kruskal-Wallis tests

beta oxidation of fatty acids), and C1QBP (mitochondrial protein synthesis) [17].

Nuclear OXPPOS genes as a group are regulated by a common set of known and novel candidate OXPPOS transcription factors

Next, we analyzed potential transcriptional regulators of the 684 (top 5 %) nuclear genes having the highest co-expression with complex I. We obtained conserved transcription factor binding sites (TFBS) for 218 unique TFs in the promoter regions of 16,298 human genes from a comparative evolutionary analysis of the genomes of 29 placental mammals [18]. This information is independent of experimental conditions and cell type and is therefore typically well suited for exploratory analysis aimed at prioritizing which TFs may regulate a biological system (see Discussion). The data include at least one conserved TFBS in 606 of the 684 genes (89 %) with the highest complex I co-expression values (Fig. 1).

Genes that co-express with complex I are significantly enriched for 12 TFs compared to the background of all

human genes after correction for testing multiple TF (Benjamini-Hochberg-corrected Fisher's exact $P < 0.05$, Table 1 and Additional file 6: Table S5): GABP, Elk1, Nrf-1, Sp1, Klf7, Sp4, Ehf, znf143, Myc, YY1, Ebox, and Tel2. Ten additional TFs are significantly enriched when they are evaluated individually (i.e. without correcting for multiple testing; Fisher's exact $P < 0.05$, Table 1 and Additional file 6: Table S5).

Virtually all known OXPPOS transcription regulators are present among these 22 enriched factors, including GABP, NRF1/2, SP1, YY1, E-box. For example, the nuclear respiratory factors 1 and 2 (NRF1 and NRF2) have ranks 3 and 20 (out of 218 TFs tested, $P = 1.0 \times 10^{-15}$ and 0.033, respectively). Furthermore, NRF1 ranks first in the analysis of known complex I genes, and is also strongly over-represented in complex II-V genes and OXPPOS assembly factors (Table 2). The most significantly enriched TF for complex I co-expressing genes is GABP/NRF2 (35 % of co-expressing genes, 2.1-fold enrichment compared to all genes, $P = 1.8 \times 10^{-28}$). NRF2 belongs to the ETS family of transcription factors, which also contains ETS1 (rank 17,

Table 1 Transcription factor binding site enrichment in promoter regions of the top 5 % complex I co-expressing nuclear genes

Rank	Transcription factor (TF)	TF occurrences in genome	TF occurrences in top 5% complex I co-expressing genes	Odds ratio	Fisher's exact <i>P</i>	Benjamini-Hochberg-corrected Fisher's exact <i>P</i>
1	GABP	2802	215	2.064	1.80E-28	3.92E-26
2	Elk1	2051	173	2.269	8.56E-27	9.33E-25
3	Nrf-1	2099	149	1.909	1.02E-15	7.38E-14
4	Sp1	7372	359	1.310	1.25E-12	6.79E-11
5	Klf7	4593	246	1.440	1.47E-11	6.40E-10
6	Sp4	4452	227	1.371	1.92E-08	6.98E-07
7	Ehf	774	61	2.120	2.25E-08	6.99E-07
8	znf143	630	50	2.134	3.63E-07	9.90E-06
9	Myc	1105	68	1.655	2.68E-05	0.00065
10	YY1	1366	74	1.457	0.00063	0.01378
11	Ebox	629	39	1.668	0.00127	0.02515
12	Tel2	1074	58	1.452	0.00264	0.04801
13	INSM1	503	31	1.658	0.00421	0.07067
14	PPAR	381	24	1.694	0.00855	0.13310
15	SF1	1173	59	1.353	0.01076	0.15631
16	PPARG	2093	97	1.246	0.01204	0.16208
17	Ets	2591	117	1.214	0.01264	0.16208
18	PU.1	839	44	1.410	0.01353	0.16383
19	KROX	2294	103	1.208	0.02223	0.25506
20	Nrf-2	1587	73	1.237	0.03256	0.35491
21	CREB	1000	48	1.291	0.04130	0.42878
22	HNF4	2119	93	1.180	0.04806	0.47620

Background: all human genes. Listed are all individually significantly enriched TFs (i.e. without correcting for multiple testing; Fisher's exact $P < 0.05$). TFs with Benjamini-Hochberg-corrected Fisher's exact $P < 0.05$ are shaded in grey. TFs with a known role in OXPHOS biogenesis are in bold See Additional file 6: Table S5 for detailed results

$P = 0.013$). Other examples of known OXPHOS regulators of complex I co-expressing genes are SP1 (rank 4, $P = 1.2 \times 10^{-12}$), YY1 (rank 10, $P = 6.3 \times 10^{-4}$), CREB (rank 21, $P = 0.041$), the E-box regulatory motif (rank 11, $P = 1.3 \times 10^{-3}$) and E-box factor c-Myc (rank 9, $P = 2.7 \times 10^{-5}$). PGC-1-

related coactivators (PRC), such as PGC-1(α) and PGC-1 β , are known to act through PPAR(α) (rank 14, $P = 8.6 \times 10^{-3}$) and PPAR γ (rank 16, $P = 0.012$). Aside from known regulators, our analysis also identified six TFs not previously linked to OXPHOS gene expression (see Discussion): ELK1

Table 2 Transcription factor binding site enrichment in promoter regions of OXPHOS subunits and assembly factors

	Transcription factor (TF)	TF occurrences in genome	TF occurrences in tested genes	Odds ratio	Fisher's exact <i>P</i>	Benjamini-Hochberg-corrected Fisher's exact <i>P</i>	
A	Complex I (n=32)	Nrf-1	2099	13	3.154	8.26E-05	
		znf143	630	5	4.042	0.00720	0.78456
		Six	19	1	26.806	0.03667	1
B	Complexes II, III, IV and V (n=34)	SF1	1173	13	5.313	2.90E-07	6.31E-05
		NR4A2	1078	11	4.891	7.00E-06	7.64E-04
		Nrf-1	2099	11	2.512	0.00264	0.19163
		Elk1	2051	10	2.337	0.00733	0.39950
		Err-alpha	958	6	3.002	0.01327	0.57839
		RXR	562	4	3.412	0.02862	1
C	Assembly factors (n=35)	GABP	2802	11	1.828	0.02848	1
		Nrf-1	2099	9	1.997	0.02973	1

Background: all human genes. Listed are all individually significantly enriched TFs (i.e. without correcting for multiple testing; Fisher's exact $P < 0.05$). TFs with Benjamini-Hochberg-corrected Fisher's exact $P < 0.05$ are shaded in grey. Numbers in parentheses indicate the number of genes for which there is conserved TFBS data. Nrf-1 is marked in bold

(rank 2, $P = 8.6 \times 10^{-27}$), KLF7 (rank 5, $P = 1.5 \times 10^{-11}$), SP4 (rank 6, $P = 1.9 \times 10^{-8}$), EHF (rank 7, $P = 2.2 \times 10^{-8}$), ZNF143 (rank 8, $P = 3.6 \times 10^{-7}$), and TEL2 (rank 12, $P = 2.6 \times 10^{-3}$).

As we have shown above, expression clustering and co-expression analysis indicate joint regulation of OXPHOS genes as a group, rather than specific regulation of individual complexes. We next asked whether there is also no evidence for complex-specific regulation in the conserved TF binding sites. Promoter regions of complex I subunits are significantly enriched only for Nrf-1 binding motifs (40.6 % of complex I genes, 3.2-fold enrichment, Fisher's exact $P = 8.3 \times 10^{-5}$, Table 2A). However, Nrf-1 is not specific for complex I genes as it is also over-represented in subunits of complexes II, III, IV and V (32.4 % of complex II-V genes, 2.5-fold enrichment, Fisher's exact $P = 2.6 \times 10^{-3}$, Table 2B) and in OXPHOS assembly factors (25.7 % of assembly factors, 2.0-fold enrichment, Fisher's exact $P = 0.030$, Table 2C). Thus, it appears that there are no significantly over-represented

transcription factors among the 218 tested that regulate specific OXPHOS complexes, confirming the patterns of general OXPHOS subunit regulation observed in the (co-)expression data.

Discussion

Disorders of the oxidative phosphorylation (OXPHOS) system are rare but devastating energy deficiencies. To date, the genetic basis of a large fraction (estimates range from 40–70 %) of these disorders remains enigmatic [4, 5]. When no mutations are found in any of the known OXPHOS subunits and assembly factors, a possible explanation may be found in the genes that control their expression, such as transcriptional (co-)activators. A specification of which of these factors control OXPHOS gene expression, and how, would be helpful.

Large-scale gene expression analyses have previously revealed co-expression of genes involved in the OXPHOS system [19–25]. The associated transcription program is moderated by a set of (co-)activators, including PGC-1 α ,

NRF1/2, YY1, and SP1. To our knowledge only one study focused on the possibility of individual expression programs for individual OXPHOS complexes [23]. In this study, only genes within OXPHOS complexes I and IV showed moderately higher degrees of co-expression with each other than with OXPHOS genes as a whole. However, no specific TFs (among 150 families tested), conserved across three organisms (human, mouse, rat), could be identified to explain this result.

We aimed to further investigate the existence of separate expression programs for individual OXPHOS complexes. To this end we investigated the transcription program for OXPHOS genes in complex I-deficient cells and assessed the regulatory elements involved. We used complex I deficient cell lines and controls in order to discriminate complex I-related expression responses upon drug treatment. To elicit a metabolic transcriptional response we incubated the cells with and without chloramphenicol, AICAR, and resveratrol. The effects of these incubations were generally similar between controls and patients. Chloramphenicol resulted in an accumulation of mitochondrial mRNA, likely due to the block in translation. Furthermore, after chloramphenicol and AICAR treatment, we observed contrasting changes in the expression of subsets of mitochondrial OXPHOS genes (COX1/ND4/ND4L/ND5/ND6 vs ATP8/ND2/ND3) (Fig. 2a).

Chloramphenicol inhibits mitochondrial translation, hence the observed changes in transcript levels are likely the consequence of disrupted mitochondrial translation. Recent studies have highlighted feedback mechanisms between mitochondrial translation and transcription. For example, ribosome subunit MRPL12 interacts with mitochondrial polymerase POLRMT to enhance mitochondrial transcription [26, 27]. In addition, POLRMT interacts with 12S rRNA methyltransferase h-mtTFB1 as a possible checkpoint for 28S and 55S ribosome assembly [28]. The changes in transcript levels that we observe upon inhibition of translation are not correlated with respiratory chain complex, position on the mitochondrial genome or mitochondrial strand of origin. How the abovementioned interactions could affect the levels of individual mitochondrial transcripts is unclear and likely partly controlled by regulatory proteins. A recent example of such a protein is FASTKD5, required for the maturation of a subset of mitochondrial OXPHOS mRNAs, primarily COX1 [29].

Although our analysis of mitochondrial and nuclear OXPHOS gene transcription did not reveal complex-specific expression patterns, we did observe a significantly different expression profile for nuclear OXPHOS subunit genes versus other genes encoding proteins localized to the mitochondria, supporting differential nuclear gene regulation of a sub-mitochondrial process. Interestingly,

OXPHOS assembly factors showed expression profiles that are significantly different from OXPHOS subunits: assembly factor expression tends to be more similar to non-OXPHOS mitochondrial genes. For example, the iron-sulfur cluster protein NUBPL (IND1) [30] is a complex I assembly factor with an expression profile very different from OXPHOS subunits (Fig. 2b) and low co-expression with complex I subunits (at ~0.3 is has the third lowest co-expression score of all 39 analyzed OXPHOS assembly factors). These findings suggest that expression of at least some assembly factors is controlled by other factors than that of subunits. This is perhaps not surprising considering that assembly factors can play multiple roles not exclusive to the biogenesis of OXPHOS complexes, for example in translation, membrane insertion, or the incorporation of prosthetic groups.

In our expression data of complex I-deficient cells, 684 genes represent the top 5 % of nuclear genes that co-express with known complex I genes. Among these genes are many subunits of other OXPHOS complexes, confirming that different OXPHOS complexes have highly similar expression profiles. Other highly enriched gene groups in the top complex I co-expressing genes are those for translation and for quality control. Of particular interest are a number of genes implicated in RNA processing and a subset of fatty acid oxidation genes. For example, ACAD9 is essential for complex I assembly and plays no obvious role in fatty acid oxidation, despite a highly conserved fatty acid oxidation active site [31, 32]. ACAD9 (Fig. 2b) and two genes actually involved in fatty acid metabolism, ETFA and ETFB, have high co-expression with complex I subunit genes (scores ~0.6), while ACADVL, ACADM, and ACADS, which are evolutionarily related to ACAD9, all have lower scores of ~0.4. Co-expression of ACAD9 and a number of key fatty acid oxidation genes with complex I hints towards a possible functional link between these two metabolic pathways.

To explore which TFs may be important for regulating genes that co-express with complex I, we made use of a previously published data set of TF binding sites that are conserved across 29 mammals [18]. The conserved TFBS are detected solely on the basis of genome sequence and are therefore independent of experimental conditions and cell type [33]. In contrast, binding sites identified in for example ChIP-sequencing experiments, such as generated by the ENCODE consortium [34], are specific to cell type and experimental conditions. Although the conserved TFBS data has been shown to agree well with experimentally measured ChIP-seq binding sites [18], only a subset of TFs have been measured across many different cell types and conditions. Therefore, sequence-conserved TFBS data such as used in this study is typically well suited for prioritizing which TFs may regulate a biological system. Indeed, we also

analyzed enrichment of TFs using TFBS data derived from ENCODE ChIP-seq peaks, either by creating various composite data sets that union all tissues and conditions measured, or by analysis of specific cell types relevant to mitochondrial functioning such as skeletal muscle and heart cells. The union data sets produced very large enrichments for almost all TFs tested, while the tissue-specific data lacked power and produced not a single over-represented TF. Thus, neither of these approaches, in our hands, were insightful for prioritizing TFs involved in complex I co-expression, or in fact for various other biological systems generally unrelated to mitochondrial function.

Analysis of conserved TF binding sites in promoter regions revealed 22 over-represented TFs compared with their genomic abundance. The enriched TFs (Table 1) correspond well with known OXPHOS regulators [35, 36]. However, several over-represented TFs have not been previously implicated in the regulation of complex I or OXPHOS in general. For example, ELK1 is the second strongest enriched TF in genes that co-express with complex I ($P = 8.6 \times 10^{-27}$) and belongs to the ETS family of transcription factors, which also includes known OXPHOS regulators NRF2, GABP, and ETS1. Interestingly, ELK1 has been linked to primary respiratory chain disease: its target genes show large differential expression between muscle cells and fibroblasts of patients [37]. EHF (ESE3, rank 7, $P = 2.2 \times 10^{-8}$) and TEL2 (ETV7, rank 12, $P = 2.6 \times 10^{-3}$) are two other ETS family members.

SP4 (rank 6, $P = 1.9 \times 10^{-8}$), together with SP1 and KLF7 (rank 5, $P = 1.5 \times 10^{-11}$) part of the Krüppel-like family of TFs, was recently implicated in the regulation of cytochrome c oxidase (OXPHOS complex IV) gene expression in primary neurons [38]. In addition, SP4 regulates the three mitochondrial transcription factors TFAM, TFB1M, and TFB2M, and the complex IV assembly protein SURF1. Thus, the high rank of this TF fits with its proposed role in OXPHOS gene regulation.

Zinc finger protein 143 (ZNF143; complex I co-expression rank 8, $P = 3.6 \times 10^{-7}$; known complex I genes rank 2, $P = 7.2 \times 10^{-3}$) is a transcriptional activator for selenocysteine tRNA (tRNA^{Sec}). During mitochondrial respiratory chain dysfunction, ZNF143 upregulates tRNA^{Sec}, which results in increased expression of glutathione peroxidase 1 (GPX1) [39]. This mechanism has been proposed to protect cells from oxidative stress damage in conditions of respiratory chain dysfunction. In addition, ZNF143 binds to HCFC1, which is a common component of active CpG island promoters and coincides with YY1 and GABP, both relevant to OXPHOS biogenesis [40]. Taken together, ZNF143 is a strongly enriched regulator of genes that co-express with complex I across expression data of complex I-deficient

patients. Further investigation of the transcription factors newly identified by our analyses may provide new clues towards gene regulation in deficiencies of the oxidative phosphorylation system.

Conclusions

To find new leads for explaining the many genetically unexplained cases of OXPHOS deficiency we have explored mitochondrial and nuclear gene expression and transcriptional elements of OXPHOS subunits and assembly factors in human complex I-deficient cells. We found that genes of the OXPHOS system co-express distinctly from other genes encoding mitochondrial proteins but found no support for distinct expression profiles for individual complexes. Genes encoding OXPHOS assembly factors follow an expression program different from that of OXPHOS subunits, suggesting that regulation of biogenesis occurs via different transcriptional activators. Many regulators of genes that co-express with complex I are well-established factors for OXPHOS biogenesis. However, for six factors, we suggest for the first time a link with transcriptional regulation of OXPHOS genes. The physiological relevance of these factors will need to be tested.

Methods

Cell culture and RNA isolation

Control (internal culture no #4996 and #MW35) and patient (internal culture no #5170 and #9170) fibroblasts were cultured in M199 medium (Life Technologies) supplemented with 10 % fetal calf serum (v/v) and penicillin/streptomycin. These cultures were exposed for 72 h in the same medium with the addition of 125 μ M chloramphenicol, 75 μ M resveratrol, 500 μ M AICAR, or 0.01 % DMSO (vehicle). Duplicate treatments were harvested as two confluent T175 flasks (~20 million cells) for two control and two complex I-deficient patient cell lines, resulting in a total of 32 samples for RNA isolation.

RNA sequencing

RNA was isolated using the Purelink RNA Mini Kit (Life Technologies). RNA was treated with DNase and quality control was performed (OD260/280 = 1.8 ~ 2.2; OD260/230 \geq 2.0; RIN \geq 7.0; 28S: 18S > 1.0). Two 2 μ g of RNA was analyzed using Illumina HiSeq2000 at least 10M clean reads per sample (BGI Genomics, Hong Kong).

RNA-seq data analysis

Raw sequence data was filtered for reads that contain adapters in their sequence (0.5 %) and with more than 50 % of low quality base calls (quality value \leq 5, 1.1 % of total reads). 98.4 % or 10,270,698 of short reads passed these criteria. After filtering the reads were mapped to the reference using SOAP2 pipeline [41] allowing for 1 or 2 mismatched bases. Between 80 and 89 % of reads, depending on the

measurement, were successfully mapped to the reference mRNAs, with 44 %–52 % uniquely to a single gene position. 18–24 % gene transcripts were covered across their full length (90–100 % of the transcript length) and 17–18 % of genes were covered for less than 10 % of their transcript length. Reads were subsequently mapped onto reference gene sequences to calculate RPKM (Reads Per Kb per Million mapped reads) [42]. This procedure resulted in expression values in at least one of the 32 samples for 19,426 genes. Of these, 13,700 genes were present in multiple experiments that allowed further analyses. The raw RPKM values were log-transformed and median-centered (median = 1.0). For analysis of the transcript levels of mtDNA-encoded genes we did not take into account non-protein coding genes, e.g., mitochondrially encoded 12S and 16S RNA (MT-RNR1, MT-RNR2) and tRNA leucine 1 (MT-TL1). Reproducibility of total mRNA measurements of the mtDNA encoded genes for the biological replicates was very high ($R^2 = 0.88$, average difference between measurements 1.9 %; 0.1 %–12 %). The transcript levels of mitochondrial genes were normalized in the same way as nuclear genes.

Co-expression calculations

For the complex I co-expression analysis we take into account all nuclear encoded subunits of the complex and its assembly factors NDUFAF1-4, TMEM126B [43], and ACAD9 [31]. Pearson correlations of expression were calculated for each of the 13,684 genes with every gene that encodes a complex I subunit or assembly factor. The correlation values are based on the expression measurements of the 32 samples. We then calculated for each gene the average co-expression with the extended complex I gene set (i.e., the genes mention above).

$$c(g, S = [NDUFA1, NDUFA2, \dots]) \\ = \frac{\text{avg}}{g' \in S} \rho(e[g], e[g']) \\ \rho(e[g], e[g']) \geq 0$$

where $c(g, S)$ is the co-expression of gene g with gene set S , where S is the extended set of complex I genes and assembly factors, ρ denotes the Pearson correlation, and $e[g]$ is the expression vector in 32 conditions and cell types for gene g .

Similarly to expression patterns observed for all OXPHOS genes, complex I subunits and their assembly factors exhibit slightly divergent transcriptional programs. Additional file 2: Figure S6 reveals that complex I core subunits cluster together separately from assembly factors. The first (and largest) group is composed mostly of core subunits (from NDUFA11, top, to NDUFA6). Two smaller categories, with respectively seven and six

subunits, additionally contain complex I assembly factors (NDUFAF1, NDUFAF5 in the second subclass; TMEM126B, NDUFAF2, NDUFAF4 in the third). Resveratrol and AICAR experiments appear to be most discriminative for the subgroup classification as the first subclass (subunits) shows low expression in resveratrol and AICAR in patients, and higher expression in AICAR-treated controls (Additional file 2: Figure S6). The smaller two subclasses of complex I genes do not exhibit such clear expression patterns. To account for the fact that subclasses fall under different transcriptional programs, we only considered Pearson correlations greater than 0. This increases the sensitivity of finding genes that fall under the transcriptional program of one of the subclasses (positive correlation), but not the other (negative correlation, which is not taken into account).

We selected a subset of 684 genes (representing the top 5 % of complex I co-expression scores) for downstream analyses. We determined this cutoff by three criteria: (i) it captures almost half (42 %) of the known OXPHOS subunits, (ii) it is close to a local peak in the frequency distribution of co-expression scores (Figs. 3 and Additional file 2: Figure S5), and (iii) the size of the resulting set of genes (684) is well suited for enrichment analysis, both on the level of functional classification and gene ontology as well as in terms of conserved transcription factor binding sites (see below).

Conserved transcription factor binding site data

Data on conserved transcription factor binding sites (TFBS) in human were obtained from a comparative analysis of 29 genomes of placental mammals, such as primates, rodents and many farm animals [18]. In this study, transcription factor (TF) regulatory motifs were collected from the TRANSFAC [44] and Jaspar [45] databases, and several protein binding microarrays [46–48]. The presence of individual motif instances (putative TFBS) was predicted across the human genome based on conservation across the 29 mammals: for each motif match in human, the smallest phylogenetic subtree was calculated that contains the human motif and aligned motifs in other species [33]. TFBS were identified at a false discovery rate of 60 % and show reasonable agreement with experimentally measured ChIP-seq binding sites [18].

To identify putative regulators of a gene, we used conserved TFBS in promoter regions of genes, which were defined as 4 kilobase (kb) windows centered at all annotated transcription start sites of the gene (i.e. 2 kb upstream and 2 kb downstream of each transcription start site). This approach identifies instances for 361 regulatory motifs corresponding to 218 unique TFs (most TFs have multiple similar binding motifs) in the promoters of 16,298 genes, with a median of 7 (average 9.19) unique TFs per target gene.

TFBS enrichment analysis

We used the Fisher's exact test to calculate statistical over-representation of TFs regulating a gene set of interest compared to a background (e.g. all genes in the human genome, or all OXPHOS genes). Enrichment *P* values were corrected for testing multiple TFs (218 in total) using the Bonferroni or Benjamini-Hochberg false discovery procedures. TFs were judged to be significantly enriched at a significance level of 5 %.

Availability of supporting data

The data sets supporting the results of this article are available in the GEO repository, GSE65634 <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65634>.

Ethics

The study has been carried out in the Netherlands in accordance with the applicable rules concerning the review of Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen. The board has approved this study and patients have provided written informed consent.

Additional files

Additional file 1: Table S1. Overview of the structural subunits and assembly factors of OXPHOS complexes as used in this study. (XLSX 67 kb)

Additional file 2: Figure S1. OXPHOS enriched cluster of genes. Figure S2. Mitochondrial OXPHOS genes respond differentially to treatments and assembly factors tend to express differently from nuclear genes encoding OXPHOS subunits (arranged by cell line). Figure S3. Total mitochondrial mRNA measured (RPKM) for mitochondrial protein coding genes. Figure S4. mRNA levels of mitochondrial genes encoding complex I subunits. Figure S5. Histogram (gray, left y-axis) and kernel density estimates (blue, right y-axis) of co-expression scores with known complex I genes. Figure S6. Dendrograms of the transcriptional response of genes encoding complex I subunits in 32 RNA-seq measurements. (DOCX 3004 kb)

Additional file 3: Table S2. OXPHOS enriched cluster of genes. (XLSX 5387 kb)

Additional file 4: Table S3. Top five percent complex I co-expressing genes. (XLSX 35 kb)

Additional file 5: Table S4. DAVID gene functional classification results of the top five percent complex I co-expressing genes. (XLSX 27 kb)

Additional file 6: Table S5. TF binding site enrichment analysis of promoter regions of the top five percent complex I co-expressing genes (full results). (XLSX 65 kb)

Abbreviations

AICAR: 5-aminoimidazole-4-carboxamide ribonucleotide; AMPK: 5' adenosine monophosphate-activated protein kinase; ATP: Adenosine triphosphate; ChIP: Chromatin immunoprecipitation; DMSO: Dimethylsulfoxide; ES: Enrichment score; mtDNA: Mitochondrial DNA; OXPHOS: Oxidative phosphorylation; RPKM: Reads per kilobase per million mapped reads; TF: Transcription factor; TFBS: Transcription factor binding site.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RV performed cell culture, treatments, RNA extraction and analysis, and drafted the manuscript. RvdL analyzed co-expression data and transcription factor binding sites, and drafted the manuscript. RS carried out transcriptomics analysis and helped to draft the manuscript. HJMS contributed to the mitochondrial gene

expression analysis. MAH helped draft the manuscript, and together with JS supervised the study. All authors read and approved the final manuscript.

Acknowledgements

We are grateful to Pouya Kheradpour for providing conserved TF binding sites in human promoter regions and to Sergio Guerrero for assistance in hierarchical clustering. R.v.d.L. and M.A.H. were supported by the Virgo consortium, funded by the Dutch government (FES0908) and the Netherlands Genomics Initiative (050-060-452). R.S. was supported by the Metakids Foundation. R.V. was supported by NWO VENI grant no 863.10.018.

Author details

¹Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, PO BOX 9101, 6500 HB Nijmegen, The Netherlands. ²Department of Clinical Genetics, Unit Clinical Genomics, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands. ³Nijmegen Center for Mitochondrial Disorders, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, PO BOX 9101, 6500 HB Nijmegen, The Netherlands. ⁴Unit Clinical Genomics, Department of Genetics and Cell Biology, School for Growth and Development and for Cardiovascular Research, Maastricht University Medical Centre, Maastricht, The Netherlands.

Received: 5 February 2015 Accepted: 27 August 2015

Published online: 15 September 2015

References

- Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. *N Engl J Med*. 2012;366(12):1132-41.
- Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. *Brain*. 2003;126(Pt 8):1905-12.
- Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S, et al. New treatments for mitochondrial disease-no time to drop our standards. *Nat Rev Neurol*. 2013;9(8):474-81.
- Neveling K, Feenstra I, Gilissen C, Hoefsloot LH, Kamsteeg EJ, Mensenkamp AR, et al. A post-hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. *Hum Mutat*. 2013;34(12):1721-6.
- Taylor RW, Pyle A, Griffin H, Blakely EL, Duff J, He L, et al. Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. *JAMA*. 2014;312(1):68-77.
- Fassone E, Rahman S. Complex I deficiency: clinical features, biochemistry and molecular genetics. *J Med Genet*. 2012;49(9):578-90.
- Vogel RO, Dieteren CE, van den Heuvel LP, Willems PH, Smeitink JA, Koopman WJ, et al. Identification of mitochondrial complex I assembly intermediates by tracing tagged NDUFS3 demonstrates the entry point of mitochondrial subunits. *J Biol Chem*. 2007;282(10):7582-90.
- Lopes Costa A, Le Bachelier C, Mathieu L, Rotig A, Boneh A, De Lonlay P, et al. Beneficial effects of resveratrol on respiratory chain defects in patients' fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling. *Hum Mol Genet*. 2014;23(8):2106-19.
- Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggio M, Fagioliari G, et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1 α axis. *Cell Metab*. 2011;14(1):80-90.
- Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, et al. A mitochondrial protein compendium elucidates complex I disease biology. *Cell*. 2008;134(1):112-23.
- da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc*. 2009;4(1):44-57.
- Catic A, Suh CY, Hill CT, Daheron L, Henkel T, Orford KW, et al. Genome-wide map of nuclear protein degradation shows NCoR1 turnover as a key to mitochondrial gene regulation. *Cell*. 2013;155(6):1380-95.
- McKeller MR, Herrera-Rodriguez S, Ma W, Ortiz-Quintero B, Rangel R, Candé C, et al. Vital function of PRELI and essential requirement of its LEA motif. *Cell Death Dis*. 2010;1:e21.
- Aras S, Bai M, Lee I, Springett R, Hüttemann M, Grossman LI. MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism. *Mitochondrion*. 2014;20C:43-51.

15. Huang X, Shi Z, Wang W, Bai J, Chen Z, Xu J, et al. Identification and characterization of a novel protein ISOC2 that interacts with p16INK4a. *Biochem Biophys Res Commun*. 2007;361(2):287–93.
16. Wessels HJ, Vogel RO, Lightowers RN, Spelbrink JN, Rodenburg RJ, van den Heuvel LP, et al. Analysis of 953 human proteins from a mitochondrial HEK293 fraction by complexome profiling. *PLoS One*. 2013;8(7):e68340.
17. Yagi M, Uchiyama T, Takazaki S, Okuno B, Nomura M, Yoshida S, et al. p32/gC1qR is indispensable for fetal development and mitochondrial translation: importance of its RNA-binding ability. *Nucleic Acids Res*. 2012;40(19):9717–37.
18. Lindblad-Toh K, Garber M, Zuk O, Lin MF, Parker BJ, Washietl S, et al. A high-resolution map of human evolutionary constraint using 29 mammals. *Nature*. 2011;478(7370):476–82.
19. Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network for global discovery of conserved genetic modules. *Science*. 2003;302(5643):249–55.
20. Bergmann S, Ihmels J, Barkai N. Similarities and differences in genome-wide expression data of six organisms. *PLoS Biol*. 2004;2(1):E9.
21. Lee HK, Hsu AK, Sajdak J, Qin J, Pavlidis P. Coexpression analysis of human genes across many microarray data sets. *Genome Res*. 2004;14(6):1085–94.
22. Shyamsundar R, Kim YH, Higgins JP, Montgomery K, Jorden M, Sethuraman A, et al. A DNA microarray survey of gene expression in normal human tissues. *Genome Biol*. 2005;6(3):R22. Erratum in: *Genome Biol*. 2005;6(9):404, 404.2.
23. van Waveren C, Moraes CT. Transcriptional co-expression and co-regulation of genes coding for components of the oxidative phosphorylation system. *BMC Genomics*. 2008;9:18.
24. Baughman JM, Nilsson R, Gohil VM, Arlow DH, Gauhar Z, Mootha VK. A computational screen for regulators of oxidative phosphorylation implicates SLIRP in mitochondrial RNA homeostasis. *PLoS Genet*. 2009;5(8):e1000590.
25. Garbian Y, Ovadia O, Dadon S, Mishmar D. Gene expression patterns of oxidative phosphorylation complex I subunits are organized in clusters. *PLoS One*. 2010;5(4):e9985.
26. Wang Z, Cotney J, Shadel GS. Human mitochondrial ribosomal protein MRPL12 interacts directly with mitochondrial RNA polymerase to modulate mitochondrial gene expression. *J Biol Chem*. 2007;282(17):12610–8.
27. Surovtseva YV, Shutt TE, Cotney J, Cimen H, Chen SY, Koc EC, et al. Mitochondrial ribosomal protein L12 selectively associates with human mitochondrial RNA polymerase to activate transcription. *Proc Natl Acad Sci U S A*. 2011;108(44):17921–6.
28. Surovtseva YV, Shadel GS. Transcription-independent role for human mitochondrial RNA polymerase in mitochondrial ribosome biogenesis. *Nucleic Acids Res*. 2013;41(4):2479–88.
29. Antonicka H, Shourbridge EA. Mitochondrial RNA Granules Are Centers for Posttranscriptional RNA Processing and Ribosome Biogenesis. *Cell Rep*. 2015. doi:10.1016/j.celrep.2015.01.030.
30. Sheftel AD, Stehling O, Pierik AJ, Netz DJ, Kerscher S, Elsässer HP, et al. Human ind1, an iron-sulfur cluster assembly factor for respiratory complex I. *Mol Cell Biol*. 2009;29(22):6059–73.
31. Nouws J, Nijtmans L, Houten SM, van den Brand M, Huynen M, Venselaar H, et al. Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. *Cell Metab*. 2010;12(3):283–94.
32. Nouws J, Nijtmans LG, Smeitink JA, Vogel RO. Assembly factors as a new class of disease genes for mitochondrial complex I deficiency: cause, pathology and treatment options. *Brain*. 2012;135(Pt 1):12–22.
33. Kheradpour P, Stark A, Roy S, Kellis M. Reliable prediction of regulator targets using 12 Drosophila genomes. *Genome Res*. 2007;17(12):1919–31.
34. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012;489(7414):57–74.
35. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. *Biochim Biophys Acta*. 2002;1576(1–2):1–14.
36. Mootha VK, Handschin C, Arlow D, Xie X, St Pierre J, Sihag S, et al. ERRalpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. *Proc Natl Acad Sci U S A*. 2004;101(17):6570–5.
37. Zhang Z, Tsukikawa M, Peng M, Polyak E, Nakamaru-Ogiso E, Ostrovsky J, et al. Primary respiratory chain disease causes tissue-specific dysregulation of the global transcriptome and nutrient-sensing signaling network. *PLoS One*. 2013;8(7):e69282.
38. Johar K, Priya A, Dhar S, Liu Q, Wong-Riley MT. Neuron-specific specificity protein 4 bigenomically regulates the transcription of all mitochondria- and nucleus-encoded cytochrome c oxidase subunit genes in neurons. *J Neurochem*. 2013;127(4):496–508.
39. Lu W, Chen Z, Zhang H, Wang Y, Luo Y, Huang P. ZNF143 transcription factor mediates cell survival through upregulation of the GPX1 activity in the mitochondrial respiratory dysfunction. *Cell Death Dis*. 2012;3:e422.
40. Michaud J, Praz V, James Faresse N, Jnbaptiste CK, Tyagi S, Schütz F, et al. HCF1 is a common component of active human CpG-island promoters and coincides with ZNF143, THAP11, YY1, and GABP transcription factor occupancy. *Genome Res*. 2013;23(6):907–16.
41. Li R, Yu C, Li Y, Lam TW, Yiu SM, Kristiansen K, et al. SOAP2: an improved ultrafast tool for short read alignment. *Bioinformatics*. 2009;25(15):1966–7.
42. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods*. 2008;5(7):621–8.
43. Heide H, Bleier L, Steger M, Ackermann J, Dröse S, Schwamb B, et al. Complexome profiling identifies TMEM126B as a component of the mitochondrial complex I assembly complex. *Cell Metab*. 2012;16(4):538–49.
44. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, et al. TRANSFAC and its module TRANSCOMP: transcriptional gene regulation in eukaryotes. *Nucleic Acids Res*. 2006;34(Database issue):D108–10.
45. Mathelier A, Zhao X, Zhang AW, Parcy F, Worsley-Hunt R, Arenillas DJ, et al. JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. *Nucleic Acids Res*. 2014;42(Database issue):D142–7.
46. Berger MF, Philippakis AA, Qureshi AM, He FS, Estep 3rd PW, Bulyk ML. Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities. *Nat Biotechnol*. 2006;24(11):1429–35.
47. Berger MF, Badis G, Gehrke AR, Talukder S, Philippakis AA, Peña-Castillo L, et al. Variation in homeodomain DNA binding revealed by high-resolution analysis of sequence preferences. *Cell*. 2008;133(7):1266–76.
48. Badis G, Berger MF, Philippakis AA, Talukder S, Gehrke AR, Jaeger SA, et al. Diversity and complexity in DNA recognition by transcription factors. *Science*. 2009;324(5935):1720–3.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

